Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Sunscreen (SPF) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
Topical OTC. Apply a broad-spectrum SPF 30+ sunscreen daily to sun-exposed skin as the last step of a morning routine, using an adequate amount (about 2 mg/cm² — roughly a nickel-sized dollop for the face, a shot-glass for the body) and reapply every ~2 hours of sun exposure and after swimming/sweating. Mineral (zinc oxide / titanium dioxide) filters are preferred if you're concerned about systemic absorption. There is no oral or systemic dose — it is not ingested. This library does not provide an ingestion protocol.
morning
Broad-spectrum SPF 30+, applied daily; mineral (zinc oxide/titanium dioxide) if concerned about absorption
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
Throughout
Ongoing (years)
Ongoing
Throughout
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · Rct
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · Rct · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Sunscreen and prevention of skin aging: a randomized trial.
Ann Intern Med (2013) · Rct · n=903
Randomized community trial (n=903): the daily sunscreen group showed no detectable increase in photoaging (skin microtopography) after 4.5 years
Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap-1-regulated matrix metalloproteinases that degrade human skin in vivo.
J Investig Dermatol Symp Proc (1998) · Review
Mechanistic model: UV activates MAP-kinase pathways and AP-1, which upregulate matrix metalloproteinases (MMPs)
Daily Use of a Facial Broad Spectrum Sunscreen Over One-Year Significantly Improves Clinical Evaluation of Photoaging.
Dermatol Surg (2016) · Open label · n=32
Single-arm prospective study (n=32): broad-spectrum SPF 30 applied daily to the face for 52 weeks
Sunscreen (SPF) has a higher evidence score (9/10 vs 8/10) and wins in 2 of 3 categories.
No known interactions between Bimatoprost (lashes) and Sunscreen (SPF) have been documented in our database. However, always consult a healthcare provider before combining supplements.